Bydureon (exenatide once-weekly) Scientific slides: GLP-1
receptor agonists and the discovery of exenatide GLP-1,
glucagon-like peptide-1. Developed with the guidance and approval
of an independent international editorial committee Prescribing
information can be found at the end of this slide deck. Date of
approval: March 2015 | Date of expiry: March 2016 Approval code:
675,057.01
Slide 2
Content guide These decks comprise a number of slides, arranged
in story order. You may find that some slides are not relevant to
your audience. Please hide these as you feel necessary All graphs
have been created in PowerPoint to enable easy amends and
translation HbA 1c values and appropriate graphs include both DCCT
(%) and IFFC (mmol/mol) units. Please delete where not appropriate
for your market DCCT, Diabetes Control and Complications Trial;
IFFC, International Federation of Clinical Chemistry and Laboratory
Medicine.
Slide 3
Executive summary This slide deck covers the following topics
and contains speaker notes to assist presentation: 1.Introduction
to Type 2 diabetes Unmet needs and barriers to treatment
Epidemiology of Type 2 diabetes Barriers to treatment (weight gain,
hypoglycaemia, adherence to treatment) The Type 2 diabetes
treatment pathway and individualised care The place of GLP-1
receptor agonists and insulin in the treatment pathway 2.GLP-1
receptor agonists and the discovery of exenatide GLP-1 mechanism of
action and the incretin effect The discovery of exenatide, the
first GLP-1 receptor agonist to receive marketing
authorisation
Slide 4
What is GLP-1? GLP-1 is an incretin hormone that is secreted by
the L-cells in the gut 1 Secreted in a nutrient-dependent manner 1
Exerts multiple glucoregulatory properties 1 Figure adapted from
Drucker DJ, et al. 2006, 1 Larsson H, et al. 1997, 2 Quddusi S, et
al. 2003, 3 and Flint A, et al. 1998. 4 GLP-1, glucagon-like
peptide-1. 1. Drucker DJ. Cell Metab 2006;3:15365; 2. Larsson H, et
al. Acta Physiol Scand 1997;160:41322; 3. Quddusi S, et al.
Diabetes Care 2003;26:791 8; 4. Flint A, et al. J Clin Invest
1998;101:51520. Fasting stateFed state Suppresses glucagon
secretion decreased hepatic glucose production 2 Suppresses
postprandial glucagon secretion decreased hepatic glucose
production 2 Slows gastric emptying 1 Stimulates glucose-dependent
insulin secretion 1 Improves first-phase insulin response 3 Reduces
appetite and food intake 4 Slide is animated
Slide 5
The way in which oral glucose elicits a greater plasma insulin
response than IV glucose is referred to as the incretin effect,
which is reduced in patients with Type 2 diabetes 1 The incretin
effect is diminished in Type 2 diabetes *p0.05 to the respective
value after the oral load. IV, intravenous. Nauck M, et al.
Diabetologia 1986;29:4652. Control 0101 0202 60 120 180 0 20 40 60
80 Time (min) Insulin (mU/L) * * * * * * * Oral glucose IV glucose
Type 2 diabetes 0101 0202 60 120 180 0 20 40 60 80 Time (min)
Insulin (mU/L) * * * Oral glucose IV glucose
Slide 6
The production of GLP-1 is diminished in people with Type 2
diabetes *p